Apotea AB/Skr APOTEA
1D1W1MYTD1Y5YMAX
Capital at risk
About Apotea AB
Apotea AB is a Swedish online pharmacy specializing in the sale of pharmaceutical products and related health items. As an e-commerce platform, Apotea offers a wide range of over-the-counter medications, prescription drugs, supplements, and wellness products. The company has established itself as a prominent digital player in the pharmaceutical retail sector in Sweden, leveraging an efficient distribution system for fast delivery services. Headquartered in Stockholm, Apotea emphasizes sustainable business practices, such as environmentally friendly packaging and delivery methods. Its strategic use of digital infrastructure enables cost-effective operations and competitive pricing, contributing to its strong market position in the e-commerce space for healthcare products in Sweden.
- Ticker
- Skr APOTEA
- Sector
- Consumer Essentials
- Primary listing
- XSTO
- Employees
- 736
- Headquarters
- Stockholm, Sweden
- Website
- www.apotea.se
Apotea AB Metrics
BasicAdvanced
kr 7.9B
32.31
kr 2.36
-
kr 0.60
0.79%
Price and volume
Market cap
kr 7.9B
52-week high
kr 97.38
52-week low
kr 54.42
Average daily volume
125K
Dividend rate
kr 0.60
Financial strength
Current ratio
1.399
Quick ratio
0.555
Long term debt to equity
0.226
Total debt to equity
0.29
Dividend payout ratio (TTM)
25.40%
Interest coverage (TTM)
25.62%
Profitability
EBITDA (TTM)
452.1
Gross margin (TTM)
19.85%
Net profit margin (TTM)
3.24%
Operating margin (TTM)
4.19%
Effective tax rate (TTM)
21.81%
Revenue per employee (TTM)
kr 10,310,000
Management effectiveness
Return on assets (TTM)
9.45%
Return on equity (TTM)
27.83%
Valuation
Price to earnings (TTM)
32.31
Price to revenue (TTM)
1.046
Price to book
8.37
Price to tangible book (TTM)
8.79
Price to free cash flow (TTM)
52.657
Free cash flow yield (TTM)
1.90%
Free cash flow per share (TTM)
1.448
Dividend yield (TTM)
0.79%
Forward dividend yield
0.79%
Growth
Revenue change (TTM)
9.38%
Earnings per share change (TTM)
-1.75%
Bulls say / Bears say
Apotea delivered Q2 2026 revenue growth of 10.9% year-on-year to SEK 2,026 million, modestly beating the forecast of SEK 2.02 billion and demonstrating continued demand momentum in its core market (Reuters).
The group maintained stable profitability in Q2 with adjusted EBIT of SEK 105 million, corresponding to a 5.2% margin, despite higher depreciation from its new Varberg fulfillment center (Reuters).
Operational capacity expanded as the Varberg center processed over 30,000 orders per day at peak, indicating improved logistics efficiency and scalability for future growth (Reuters).
Rising inventory levels tied up capital as stock rose above SEK 850 million at quarter-end, contributing to weaker operating cash flow and increased working capital risk (Reuters).
The apotea.no launch in Norway remains at an early stage with minimal marketing spend and limited customer traction, making international expansion benefits uncertain in the near term (Reuters).
Net revenue growth slowed to 10.5% in Q1 2026 from 15.2% a year earlier, signalling a deceleration in demand growth in its core Swedish market (Apotea IR Q1 2026).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing Apotea AB
AllEURGBPUSD
Fund name | Fund size | Skr APOTEA weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.03% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.03% |
iShares Digitalisation$DGTL | $793M | 0.02% |
iShares Digitalisation£DGIT | £585M | 0.02% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.